3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
2
Lymphoid
2
Gynecologic
2
Tumor-Agnostic
1
Thoracic
1
Other hematologic neoplasm
1
Head & Neck
1
Genitourinary
1
Gastrointestinal
1
Conditions
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Carboplatin
205
pembrolizumab
169
Pemetrexed
144
Cisplatin
126
Paclitaxel
78
durvalumab
75
osimertinib
70
Nivolumab
68
Docetaxel
66
Specimen Handling
64
atezolizumab
60
Magnetic Resonance Spectroscopy
54
Etoposide
47
Gemcitabine
46
Radiotherapy
45
Radiosurgery
40
130-nm albumin-bound paclitaxel
36
Drug Therapy
33
Bevacizumab
29
Cetuximab
28
Ipilimumab
27
cemiplimab
25
Taxes
24
tislelizumab
21
Immunoglobulin G
21
Radiation
20
Platinum
20
Biopsy
20
amivantamab
19
Disulfides
19
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Diphenhydramine
×
Thoracic
×
90 days
×
Clear all
NCT04165096
2026-05-13
MK-3475-01C
Merck Sharp & Dohme LLC
Phase 2
Completed
128 enrolled
14 charts